NC100100, a new echo contrast agent for the assessment of myocardial perfusion--safety and comparison with technetium-99m sestamibi single-photon emission computed tomography in a randomized multicenter study.

Binder, Thomas;Assayag, Patrick;Baer, Frank;Flachskampf, Frank;Lindvall, Kaj;et.al.
(1999) Clinical Cardiology (Hoboken) : an indexed and peer-reviewed journal for advances in the treatment of cardiovascular disease — Vol. 22, n° 4, p. 273-282 (1999)

Files

ClinCardiol199922273-282.pdf
  • Restricted Access
  • Adobe PDF
  • 1.75 MB
Request a copy

Details

Authors
  • Binder, Thomas
    Author
  • Assayag, Patrick
    Author
  • Baer, Frank
    Author
  • Flachskampf, Frank
    Author
  • Vanoverschelde, Jean-LouisUCLouvain
    Author
  • Lindvall, Kaj
    Author
Show more
Abstract
Myocardial contrast echocardiography using second-generation agents has been proposed to study myocardial perfusion. A placebo-controlled, multicenter trial was conducted to evaluate the safety, optimal dose, and imaging mode for NC100100, a novel intravenous second-generation echo contrast agent, and to compare this technique with technetium-99m sestamibi (MIBI) single-photon emission computed tomography (SPECT).
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Binder, T., Assayag, P., Baer, F., Flachskampf, F., Kamp, O., Nienaber, C., Nihoyannopoulos, P., Piérard, L., Steg, G., Vanoverschelde, J.-L., Van der Wouw, P., Meland, N., Marelli, C., & Lindvall, K. (1999). NC100100, a new echo contrast agent for the assessment of myocardial perfusion--safety and comparison with technetium-99m sestamibi single-photon emission computed tomography in a randomized multicenter study. Clinical Cardiology (Hoboken) : an indexed and peer-reviewed journal for advances in the treatment of cardiovascular disease, 22(4), 273-282. https://doi.org/10.1002/clc.4960220405 (Original work published 1999)